Measuring cognitive impairment and monitoring cognitive decline in Huntington’s disease: a comparison of assessment instruments
-
Published:2023-07-18
Issue:
Volume:
Page:
-
ISSN:0340-5354
-
Container-title:Journal of Neurology
-
language:en
-
Short-container-title:J Neurol
Author:
Horta-Barba AndreaORCID, Martinez-Horta Saul, Pérez-Pérez Jesús, Puig-Davi Arnau, de Lucia Natascia, de Michele Giuseppe, Salvatore Elena, Kehrer Stefanie, Priller Josef, Migliore Simone, Squitieri Ferdinando, Castaldo Anna, Mariotti Caterina, Mañanes Veronica, Lopez-Sendon Jose Luis, Rodriguez Noelia, Martinez-Descals Asunción, Júlio Filipa, Januário Cristina, Delussi Marianna, de Tommaso Marina, Noguera Sandra, Ruiz-Idiago Jesús, Sitek Emilia J., Wallner Renata, Nuzzi Angela, Pagonabarraga Javier, Kulisevsky Jaime,
Abstract
Abstract
Background
Progressive cognitive decline is an inevitable feature of Huntington’s disease (HD) but specific criteria and instruments are still insufficiently developed to reliably classify patients into categories of cognitive severity and to monitor the progression of cognitive impairment.
Methods
We collected data from a cohort of 180 positive gene-carriers: 33 with premanifest HD and 147 with manifest HD. Using a specifically developed gold-standard for cognitive status we classified participants into those with normal cognition, those with mild cognitive impairment, and those with dementia. We administered the Parkinson’s Disease-Cognitive Rating Scale (PD-CRS), the MMSE and the UHDRS cogscore at baseline, and at 6-month and 12-month follow-up visits. Cutoff scores discriminating between the three cognitive categories were calculated for each instrument. For each cognitive group and instrument we addressed cognitive progression, sensitivity to change, and the minimally clinical important difference corresponding to conversion from one category to another.
Results
The PD-CRS cutoff scores for MCI and dementia showed excellent sensitivity and specificity ratios that were not achieved with the other instruments. Throughout follow-up, in all cognitive groups, PD-CRS captured the rate of conversion from one cognitive category to another and also the different patterns in terms of cognitive trajectories.
Conclusion
The PD-CRS is a valid and reliable instrument to capture MCI and dementia syndromes in HD. It captures the different trajectories of cognitive progression as a function of cognitive status and shows sensitivity to change in MCI and dementia.
Funder
Universitat Autònoma de Barcelona
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference43 articles.
1. Hart EP, Dumas EM, Giltay EJ, Middelkoop HAM, Roos RAC (2013) Cognition in Huntington’s disease in manifest, premanifest and converting gene carriers over ten years. J Huntingtons Dis 2(2):137–147 2. Zhang Y, Zhou J, Gehl CR, Long JD, Johnson H, Magnotta VA et al (2021) Mild cognitive impairment as an early landmark in Huntington’s disease. Front Neurol 12(July):1–10 3. Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM et al (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75(6):500–507 4. Horta-Barba A, Martínez-Horta S, Pérez-Pérez J, Sampedro F, Puig-Davi A, Pagonabarraga J et al (2022) Measuring the functional impact of cognitive impairment in Huntington’s disease. J Neurol [Internet] 269(7):3541–3549. https://doi.org/10.1007/s00415-021-10955-2 5. Martinez-Horta S, Sampedro F, Horta-Barba A, Perez-Perez J, Pagonabarraga J, Gomez-Anson B et al (2020) Structural brain correlates of dementia in Huntington’s disease. NeuroImage Clin [Internet] 28(1):102415. https://doi.org/10.1016/j.nicl.2020.102415
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|